Prostate Cancer | Specialty

The OncLive Prostate Cancer condition center page is a comprehensive resource for clinical news and expert insights on how to approach treatment for patients with nonmetastatic, castration-resistant, or castration-sensitive prostate cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, ongoing research, and treatment advances with androgen receptor inhibitors, PARP inhibitors, and more in prostate cancer.

Second Cycle of Medicare Drug Price Negotiations Includes 4 Oncologic Agents

January 22nd 2025

The CMS has selected 15 drugs covered under Medicare Part D for the second cycle of the Drug Price Negotiation Program, including enzalutamide, pomalidomide, palbociclib, and acalabrutinib.

Rapid, At-Home PSA Screening Test Gains Approval in UAE for Early Detection of Prostate Cancer

January 21st 2025

The Fortel PSA Screening Test has been approved by the United Arab Emirates MOHAP for the rapid detection of early signs of prostate cancer.

Development of LAVA-1207 Discontinues in mCRPC

January 20th 2025

The development of LAVA-1207 for metastatic castration-resistant prostate cancer has been discontinued.

The OncFive: Top Oncology Articles for the Week of 1/12

January 18th 2025

Sotorasib doublet gets approved for KRAS G12C–mutated CRC, acalabrutinib triplet is cleared for previously untreated MCL, and more from OncLive.

Dr Park on Patient and Disease Factors that Affect Treatment Decisions for mHSPC

January 13th 2025

Chandler Park, MD, FACP, discusses patient characteristics, disease factors, and drug mechanisms of action that influence treatment decisions in mHSPC.

PDUFA Date Set for 3-Month Variation of Leuprolide Mesylate in Advanced Prostate Cancer

January 13th 2025

The FDA has set the PDUFA date for the 3-month, 21-mg variation of leuprolide mesylate in advanced prostate cancer for August 29, 2025.

CAN-2409 Improves DFS in Intermediate/High-Risk Localized Prostate Cancer

December 11th 2024

CAN-2409 plus valacyclovir and radiation therapy significantly improved DFS in intermediate- to high-risk localized prostate cancer.

Evolving Treatment Strategies: Managing Advanced Prostate Cancer

December 10th 2024

FDA Grants Fast Track Designation to PT217 for Neuroendocrine Prostate Cancer

December 5th 2024

The FDA granted fast track designation to PT217 for the treatment of patients with metastatic de novo or treatment-emergent neuroendocrine prostate cancer.

The OncFive: Top Oncology Articles for the Week of 11/24

November 30th 2024

Belantamab mafodotin is under FDA review in multiple myeloma, and Suneel Kamath, MD, highlights pancreatic cancer awareness month.

Dr Tawagi on the Growing Role of Precision Medicine in Prostate Cancer

November 27th 2024

Karine Tawagi, MD, discusses the use of targeted therapies in the management of metastatic prostate cancer.

Capivasertib Plus Abiraterone/ADT Improves rPFS in PTEN-Deficient mHSPC

November 25th 2024

Capivasertib plus abiraterone and ADT improved rPFS in PTEN-deficient metastatic hormone-sensitive prostate cancer.

FDA Accepts sNDA for Darolutamide Plus ADT in Metastatic Hormone-Sensitive Prostate Cancer

November 21st 2024

The FDA has accepted a sNDA for darolutamide plus ADT in metastatic hormone-sensitive prostate cancer.

Kidney Cancer NCCN Guidelines Receive Major Updates, Prostate Cancer Adds Targeted Agents

November 21st 2024

Sandy Srinivas, MD, details updates from 2024 in the kidney and prostate cancer NCCN guidelines and agents/trials to look forward to in 2025.

The OncFive: Top Oncology Articles for the Week of 11/10

November 16th 2024

New datopotamab deruxtecan BLA in NSCLC filed to FDA, radiopharmaceutical meets rPFS end point in PSMA+ prostate cancer, and more.

177Lu-PSMA-I&T Meets rPFS End Point in PSMA+ mCRPC

November 13th 2024

177Lu-PSMA-I&T improved radiographic progression-free survival vs hormonal therapy in PSMA-positive metastatic castration-resistant prostate cancer.

Dr Garrot on Lutetium Lu 177 Vipivotide Tetraxetan in Older Patients with MCRPC

November 7th 2024

Louis Crain Garrot, MD, discusses the role of lutetium Lu 177 in older patients with metastatic castration-resistant prostate cancer.

ESSA Discontinues Phase 2 Study of Masofaniten Plus Enzalutamide in mCRPC

November 1st 2024

The phase 2 study of masofaniten plus enzalutamide in mCRPC naive to second-generation antiandrogen therapy has been discontinued.

Novel Prostate Cancer Treatment Increases Overall Survival Rates for Late-Stage Prostate Cancer Patients

October 31st 2024

Results of the TALAPRO-2 trial showed that a novel prostate cancer therapy has a higher overall survival rate compared to the standard of care drug alone.

Patients Characteristics, Sequencing Considerations Are Vital in Prostate Cancer Management

October 30th 2024

Bradley C. Carthon, MD, PhD, discusses recent data and the evolving treatment landscape in prostate cancer.